Medicare Medical Policy

Apheresis (Therapeutic Pheresis)

MEDICARE MEDICAL POLICY NUMBER: 310

MEDICARE COVERAGE CRITERIA ................................................................. 2
POLICY CROSS REFERENCES .................................................................. 3
POLICY GUIDELINES ............................................................................ 3
REGULATORY STATUS ........................................................................ 3
BILLING GUIDELINES AND CODING .................................................. 4
REFERENCES ..................................................................................... 4
POLICY REVISION HISTORY ................................................................. 4

INSTRUCTIONS FOR USE: Company Medicare Medical Policies serve as guidance for the administration of plan benefits and do not constitute medical advice nor a guarantee of coverage. Company Medicare Medical Policies are reviewed annually to guide the coverage or non-coverage decision-making process for services or procedures in accordance with member benefit contracts (otherwise known as Evidence of Coverage or EOCs) and Centers of Medicare and Medicaid Services (CMS) policies, manuals, and other CMS rules and regulations. In the absence of a CMS coverage determination or specific regulation for a requested service, item or procedure, Company policy criteria or applicable utilization management vendor criteria may be applied. These are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

The Company reserves the right to determine the application of Medicare Medical Policies and make revisions to these policies at any time. Any conflict or variance between the EOC and Company Medical Policy will be resolved in favor of the EOC.

SCOPE: Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).
MEDICARE COVERAGE CRITERIA

IMPORTANT NOTE: More than one Centers for Medicare and Medicaid Services (CMS) reference may apply to the same health care service, such as when more than one coverage policy is available (e.g., both an NCD and LCD exist). All references listed should be considered for coverage decision-making. The Company uses the most current version of a Medicare reference available at the time of publication; however, these websites are not maintained by the Company, so Medicare references and their corresponding hyperlinks may change at any time. If there is a conflict between the Company Medicare Medical Policy and CMS guidance, the CMS guidance will govern.

<table>
<thead>
<tr>
<th>Service</th>
<th>Medicare Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apheresis (Therapeutic Pheresis) for Familial Hypercholesterolemia (CPT 36516)</td>
<td>Local Coverage Article (LCA): Therapeutic Apheresis for Familial Hypercholesterolemia (A54543)</td>
</tr>
</tbody>
</table>
| Apheresis (Therapeutic Pheresis) for Other Indications (36511-36516) | National Coverage Determination (NCD): Apheresis (Therapeutic Pheresis) (110.14)  

NOTE: Neither the above NCD nor LCA indicate selective high-density lipoprotein (HDL) delipidation and apheresis is a covered procedure. Therefore, Company medical policy criteria will apply (see below). |
| Extracorporeal photopheresis (CPT 36522) | NCD: Extracorporeal Photopheresis (110.4)  

NOTE: Medicare coverage of extracorporeal photopheresis used for the treatment of bronchiolitis obliterans syndrome (BOS) following lung allograft transplant requires the extracorporeal photopheresis to be provided under an approved clinical research study. As of the date of policy development, there is only one Medicare approved study, which can be found on the Medicare website. |
| Selective high-density lipoprotein (HDL) delipidation and apheresis (CPT 0342T) | Company medical policy for Apheresis (Therapeutic Pheresis)  

1. This service is considered not medically necessary for Medicare based on the Company medical policy. Services deemed “investigational” are considered not medically necessary for Medicare Plan members. See Policy Guidelines below. |

IMPORTANT NOTICE: While some services or items may appear medically indicated for an individual, they may also be a direct exclusion of Medicare or the member’s benefit plan. Such excluded services or items by Medicare and member EOCs include, but are not limited to, services or procedures considered to be cosmetic, not medical in nature, or those considered not medically reasonable or necessary under Title XVIII of the Social Security Act, §1862(a)(1)(A). If there is
uncertainty regarding coverage of a service or item, please review the member EOC or submit a pre-service organization determination request. Note that the Medicare Advance Beneficiary Notice of Noncoverage (ABN) form cannot be used for Medicare Advantage members. (Medicare Advance Written Notices of Non-coverage. MLN006266 May 2021)

**POLICY CROSS REFERENCES**

None

The full Company portfolio of Medicare Medical Policies is available online and can be accessed here.

**POLICY GUIDELINES**

**MEDICARE AND MEDICAL NECESSITY**

The Company policy for *PHA Medicare Medical Policy Development and Application* (MP50) provides details regarding Medicare’s definition of medical necessity and the hierarchy of Medicare references and resources during the development of medical policies, as well as the Plan’s use of evidence-based processes for policy development. In the absence of Medicare coverage policies (e.g., manual, national coverage determination [NCD], local coverage determination [LCD], article [LCA], etc.) which addresses the medical necessity of a given medical service, Medicare regulatory guidelines do allow Medicare Advantage Organizations (MAOs) to make their own coverage determinations, as long as the MAO applies an objective, evidence-based process, based on authoritative evidence. (*Medicare Managed Care Manual, Ch. 4, §90.5*)

Following an evidence-based assessment of current peer-reviewed medical literature, the Company may consider certain medical services or technologies to be “investigational.” The term “investigational” is not limited to devices or technologies which have not received the appropriate governmental regulatory approval (e.g., U.S. Food and Drug Administration [FDA]), but rather may also mean the procedure, device, or technology does not meet all of the Company’s technology assessment criteria, as detailed within the Company policy for *Definition: Experimental/Investigational* (MP5).

Only medically reasonable and necessary services or items which treat illness or injury are eligible for Medicare coverage, as outlined in *Title XVIII of the Social Security Act, §1862(a)(1)(A)*. Thus, services which lack scientific evidence regarding safety and efficacy because they are investigational are “not medically reasonable or necessary” for Medicare Plan members. (*Medicare Claims Processing Manual, Ch. 23, §30 A*)

**REGULATORY STATUS**

**U.S. FOOD & DRUG ADMINISTRATION (FDA)**

While clearance by the Food and Drug Administration (FDA) is a prerequisite for Medicare coverage, the 510(k) premarket clearance process does not in itself establish medical necessity. Medicare payment policy is determined by the interaction of numerous requirements, including but not limited to, the availability of a Medicare benefit category and other statutory requirements, coding and pricing guidelines, as well as national and local coverage determinations and clinical evidence.
BILLING GUIDELINES AND CODING

GENERAL

See the associated Medicare Claims Processing Manual, Chapter 4 - Medicare Claims Processing Manual, Chapter 4 - Part B Hospital (Including Inpatient Hospital Part B and OPPS), §231.9 - Billing for Pheresis and Apheresis Services for general billing guidance for therapeutic apheresis.

See the associated Medicare Claims Processing Manual, Chapter 32 – Billing Requirements for Special Services, §190 – Billing Requirements for Extracorporeal Photopheresis for general billing guidance for extracorporeal photopheresis.

| CODES* |
|------------------|---------------------------------------------------------------|
| CPT              | Therapeutic apheresis with selective HDL delipidation and plasma reinfusion |
| 0342T            | Therapeutic apheresis; for white blood cells                  |
| 36511            | Therapeutic apheresis; for red blood cells [red blood cell exchange] |
| 36512            | Therapeutic apheresis; for platelets                           |
| 36513            | Therapeutic apheresis; for plasma pheresis                     |
| 36514            | Therapeutic apheresis; with extracorporeal immunoadsorption, selective adsorption or selective filtration and plasma reinfusion |
| 36516            | Photopheresis, extracorporeal                                  |
| HCPCS            | None                                                           |

*Coding Notes:

- The code list above is provided as a courtesy and may not be all-inclusive. Inclusion or omission of a code from this policy neither implies nor guarantees reimbursement or coverage. Some codes may not require routine review for medical necessity, but they are subject to provider contracts, as well as member benefits, eligibility and potential utilization audit. According to Medicare, “presence of a payment amount in the MPFS and the Medicare physician fee schedule database (MPFSDB) does not imply that CMS has determined that the service may be covered by Medicare.” The issuance of a CPT or HCPCS code or the provision of a payment or fee amount by Medicare does not make a procedure medically reasonable or necessary or a covered benefit by Medicare. (Medicare Claims Processing Manual, Chapter 23 - Fee Schedule Administration and Coding Requirements, §30 - Services Paid Under the Medicare Physician’s Fee Schedule, A. Physician’s Services)

- All unlisted codes are reviewed for medical necessity, correct coding, and pricing at the claim level. If an unlisted code is submitted for non-covered services addressed in this policy then it will be denied as not covered. If an unlisted code is submitted for potentially covered services addressed in this policy, to avoid post-service denial, prior authorization is recommended.

- See the non-covered and prior authorization lists on the Company Medical Policy, Reimbursement Policy, Pharmacy Policy and Provider Information website for additional information.

- HCPCS/CPT code(s) may be subject to National Correct Coding Initiative (NCCI) procedure-to-procedure (PTP) bundling edits and daily maximum edits known as “medically unlikely edits” (MUEs) published by the Centers for Medicare and Medicaid Services (CMS). This policy does not take precedence over NCCI edits or MUEs. Please refer to the CMS website for coding guidelines and applicable code combinations.

REFERENCES

None

POLICY REVISION HISTORY
<table>
<thead>
<tr>
<th>DATE</th>
<th>REVISION SUMMARY</th>
</tr>
</thead>
<tbody>
<tr>
<td>11/2022</td>
<td>New Medicare Advantage medical policy (converted to new format 2/2023)</td>
</tr>
</tbody>
</table>